|CNAT -- USA Stock|| |
USD 4.99 0.02 0.40%
CFO, Principal Financial Officer, COO, Executive Vice President
Mr. Keith W. Marshall, Ph.D. is Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President of the company. He was Chief Financial Officer and Head of Corporationrationrate Development since 2015 at Torque Therapeutics, where his responsibilities included finance, operations, human resources, corporate strategy and business development. He served as Managing Director and Advisor in Healthcare Investment Banking from 2012 to 2014 at GCA Savvian Advisors, where he provided strategic counsel to healthcare companies, and continued from 2014 to 2015 at TAG Healthcare Advisors under an alliance with GCA Savvian. Dr. Marshall was Managing Director from 2011 to 2012 at Sagent Advisors Managing Director, Cofounder, and Chief Financial Officer from 2008 to 2011 at Montgomery, Marshall Healthcare Partners Managing Director of Healthcare Investment Banking from 2003 to 2008 at Montgomery Co. and Associate in Healthcare Investment Banking from 2001 to 2003 at JPMorgan HQ with additional responsibilities at JPMorgan Partners
President Since 2017 MBA
Marshall previously worked as a Research Associate from 1990 to 1993 at ImmuLogic Pharmaceutical Corporationrationrationration, where he performed research under a collaboration with Merck around inhibition of MHC Class II molecules for autoimmune disease therapy. He holds an M.B.A. with concentrations in Finance, Strategy, and Entrepreneurship from the University of Chicago ? Booth School of Business; a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco; and an A.B. in Biology from Washington University in St. Louis.
Keith Marshall Latest Insider Activity
The company has return on total asset (ROA)
of (14.76) %
which means that it has lost $14.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (87.78) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 13.34 M in liabilities with Debt to Equity (D/E) ratio of 57.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals has Current Ratio of 2.36 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. The company was founded in 2005 and is headquartered in San Diego, California. Conatus Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 33 people.Conatus Pharmaceuticals (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 33 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Conatus Pharmaceuticals Leadership Team
|Edward Smith, President, MBA|
|Michelle Vandertie, Executive|
|Dan Kisner, Director|
|James Scopa, Director|
|Steven Mento, CEO|
|Daniel Kisner, Director|
|Preston Klassen, Director|
|David Hale, Chairman|
|Harold Wart, Director, Ph.D|
|William LaRue, Director, MBA|
|Alfred Spada, Founder, Ph.D|
|Charles Cashion, President, MBA|
|Daniel Ripley, President, MBA|
|Keith Marshall, President, MBA|
|Louis Lacasse, Director, MBA|
|Shahzad Malik, Director|
|David Hagerty, President|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on Conatus Pharmaceuticals. What is your opinion about investing in Conatus Pharmaceuticals? Are you bullish or bearish?
and pair trading evaluation for Conatus Pharmaceuticals and NantKwest
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return